人民财讯11月6日电，11月6日，在2025可持续全球领导者大会江苏专场、第二届国联投资人大会上，无 锡国联集团宣布，国联集团生态联盟正式启动。联盟汇聚华为、阿斯利康、中金资本等企业与机构，旨 在共同打造"资本驱动、产业协同、服务赋能"的协同生态体系。开幕式上同步进行了项目签约和基金签 约。 据悉，2025年国联集团完成投资项目394个，投资总规模620亿元，重点覆盖生物医药、集成电路、先进 制造、双碳节能、人工智能等领域，合作新设基金89支，基金总规模342亿元，招引28个项目落地无 锡，投资总规模达178亿元。 ...

Core Viewpoint - Xishan Technology (688576) reported a revenue of 336 million yuan and a net profit attributable to shareholders of 98.67 million yuan for 2024, with a basic earnings per share of 1.97 yuan [1] Financial Performance - The company proposed a profit distribution plan of 10 yuan per 10 shares, totaling 45.19 million yuan in cash dividends, which accounts for 45.80% of the net profit for 2024 [1] - The total amount for cash dividends and share buybacks reached 499.5 million yuan, representing 501.81% of the net profit for the period [1] Business Strategy and Market Position - The company maintains its strategic positioning as a "provider of overall solutions for minimally invasive surgical tools," focusing on business line layout and expansion [1] - The company has seen steady growth in surgical power consumables, particularly in neurosurgery, orthopedics, and ENT fields, with consumable revenue increasing by over 40% year-on-year [1] Product Development and R&D Investment - Significant growth was noted in energy surgical equipment, with ultrasound bone knife consumables and plasma device consumables showing remarkable increases, particularly the plasma products which achieved revenue breakthroughs for the first time [2] - The company increased its R&D personnel by 19% and R&D expenses by 18.79%, reaching 55.24 million yuan in 2024 [2] - R&D investment as a percentage of revenue has consistently increased from 11.42% in 2022 to 16.42% in 2024, indicating a strong commitment to innovation [2] Technological Advancements - The company made significant breakthroughs in the field of flexible endoscopes, overcoming core technical bottlenecks in electronic digestive tract flexible endoscopes, with product registration progressing smoothly [2] Future Growth Strategy - The company plans to continue increasing R&D investment, focusing on hospital user development and usage enhancement, while actively expanding into overseas markets [3] - The dual growth strategy of "internal development" and "external expansion" will be pursued, supported by a "innovation-driven" and "capital-driven" approach [3]